Silo Pharma (NASDAQ: SILO) announced that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices' AMD AI Developer Program. The program provides QwikAgents with access to AMD Developer Cloud credits, AI development tools, training resources, and a global developer community. According to the company, this participation is expected to accelerate the development, testing, optimization, and deployment of its AI agent platform across consumer and enterprise applications.
QwikAgents is developing a platform that enables users to deploy persistent AI agents for tasks including research, content generation, scheduling, coding, and workflow automation. Silo stated that participation in the AMD AI Developer Program is expected to support platform performance, agent reliability, and scalable deployment as QwikAgents expands its capabilities for individuals, developers, small businesses, and enterprise customers. The full press release is available at https://ibn.fm/313SC.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories. More information is available at silopharma.com.
This development marks a strategic expansion for Silo Pharma into the AI sector through its subsidiary. By leveraging AMD's resources, QwikAgents aims to enhance its platform's performance and scalability, potentially positioning itself in the competitive AI agent market. The acceptance into the AMD AI Developer Program also signals recognition of QwikAgents' technology and its potential to address real-world automation needs.
For investors, the latest news and updates regarding SILO are available in the company's newsroom at https://ibn.fm/SILO. Silo Pharma continues to diversify its operations, balancing its core biopharmaceutical pipeline with emerging technology ventures.
